IRX Therapeutics to Present Phase 2 Results at 7th International Conference on Head and Neck Cancer

NEW YORK–(EMWNews)–IRX Therapeutics, a privately-held company dedicated to the discovery

and development of proprietary therapies for the treatment of cancer

and viral diseases, today announced that a symposium on findings from

its Phase 2 clinical trial of IRX-2 will be held on July 22, 2008 at

6:30 am (PDT) during the 7^th International

Conference on Head and Neck Cancer at the San Francisco Marriot Hotel.

The American Head and Neck Society’s

International Conference on Head and Neck Cancer has been the world’s

pre-eminent meeting for head and neck cancer since its inception in

1984. Approximately 1,600 surgeons, oncologists, scientists and allied

health professionals are expected to attend.

The symposium, chaired by Dr. Gregory T. Wolf, current President of the

American Head and Neck Society, titled, “New

Paradigm for the Treatment for Head and Neck Cancer”

will include three presentations:

Arlene A. Forastiere, M.D., will present “Overview

of Current Therapies for Head and Neck Cancer.”

Dr. Forastiere is Professor of Oncology, Otolaryngology, Head and Neck

Surgery and Radiation Oncology at The Sidney Kimmel Comprehensive Cancer

Center at Johns Hopkins University.

Theresa L. Whiteside, Ph.D. will present “Overcoming

Immunosuppressive Effects in Head and Neck Cancer.”

Dr. Whiteside is Professor of Pathology, Immunology and Otolaryngology

and is Director of the Immunologic Monitoring and Cellular Products

Laboratory at the University of Pittsburgh School of Medicine.

Gregory T. Wolf, M.D., F.A.C.S., the Principal Investigator for the

Phase 2 trial of IRX-2, will present “IRX-2:

Promising New Immunotherapy for Head and Neck Cancer.”

Dr. Wolf is the Professor and Chair, Department of Otolaryngology and

Head and Neck Surgery at the University of Michigan as well as Director

of the University of Michigan Head and Neck Oncology SPORE Program.

Following the presentations there will be a panel discussion moderated

by Dr. Wolf on the role of immunotherapy in head and neck cancer.

IRX Therapeutics will also be sponsoring an exhibit booth at the

Conference highlighting the upcoming INSPIRE trial, a global Phase 3

clinical trial of IRX-2 in head and neck cancer.

About Head and Neck Cancer

Head and neck cancer is a deadly disease that often goes undiagnosed

until it is at an advanced stage. There are 500,000 new cases worldwide

each year, with about 45,000 new cases in the United States. Head and

neck cancer is associated with high rates of recurrence and mortality

and is understood to be highly immunosuppressive. The current standard

of care for newly diagnosed head and neck cancer is primarily curative

surgery followed by radiation therapy or, in some cases, chemoradiation.

For patients indicated for curative surgery, there is no approved

neoadjuvant therapy. The immunosuppressive nature of head and neck

cancer creates a potential role for immunotherapy as a neoadjuvant

intervention in the treatment of this disease.

About IRX Therapeutics

IRX Therapeutics is a privately-held immunotherapy company founded by

John W. Hadden, M.D., a pioneer in the field of Immunopharmacology. The

Company’s product platform seeks to restore

an effective cellular immune response for the treatment of advanced

cancers and viral diseases by correcting both dendritic cell and T-cell

defects. An effective immune response is essential for the eradication

of viruses and tumors.

The Company’s lead product, IRX-2

(citoplurikin), received Fast Track designation by the Food and Drug

Administration. Phase 1/2 and Phase 2 clinical trials in late-stage head

and neck cancer patients have been completed.

For more information on IRX Therapeutics, please visit the Company’s

website at http://www.irxtherapeutics.com.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions